EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases

Cancer Chemotherapy and Pharmacology

Volumn 78, Issue 6, 2016, Pages 1305-1310

  Zhao, Jing ^a   Ye, Xin ^b   Xu, Yan ^a   Chen, Minjiang ^a   Zhong, Wei ^a   Sun, Yun ^b   Yang, Zhenfan ^b   Zhu, Guanshan ^b   Gu, Yi ^b   Wang, Mengzhao ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Brain metastasis; Cerebrospinal fluid; EGFR mutation testing; Leptomeningeal metastasis; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MENINGEAL METASTASIS; MIDDLE AGED; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BLOOD; CEREBROSPINAL FLUID; GENETICS; LUNG TUMOR; MENINGIOMA; MUTATION; SECONDARY;

ADULT; CARCINOMA, NON-SMALL-CELL LUNG; ERBB RECEPTORS; FEMALE; GEFITINIB; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; MUTATION; QUINAZOLINES;

EID: 84992028362     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-3155-y     Document Type: Article

References (20)

1. Lee Y, Han JY, Kim HT, Yun T, Lee GK, Kim HY et al (2013) Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. J Neurooncol 115:95–101
2. Langer CJ, Mehta MP (2005) Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23:6207–6219
3. Lee YJ, Choi HJ, Kim SK, Chang J, Moon JW, Park IK et al (2010) Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 116:1336–1343
4. Rhodes CH, Honsinger C, Sorenson GD (1994) Detection of tumor-derived DNA in cerebrospinal fluid. J Neuropathol Exp Neurol 53:364–368
5. Yang H, Cai L, Zhang Y, Tan H, Deng Q, Zhao M et al (2014) Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases. J Mol Diagn 16:558–563
6. Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT et al (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103:2344–2348
7. Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B et al (2009) EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J 33:436–440
8. Popat S, Hughes S, Papadopoulos P, Wilkins A, Moore S, Priest K et al (2007) Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer 56:135–137
9. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D et al (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4:162ra154
10. Zhu G, Ye X, Dong Z, Lu YC, Sun Y, Liu Y et al (2015) Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer. J Mol Diagn 17:265–272
11. Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J et al (2016) Plasma EGFR T790 M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep 6:20913
12. Jones HK, Stafford LE, Swaisland HC, Payne R (2002) A sensitive assay for ZD1839 (Iressa) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials. J Pharm Biomed Anal 29:221–228
13. Zhao J, Chen M, Zhong W, Zhang L, Li L, Xiao Y et al (2013) Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer 14:188–193
14. Camidge DR, Pao W, Sequis L (2014) V, Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 11:473–481
15. Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, Shukuya T et al (2016) Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. Respir Investig 54(1):14–19
16. Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S et al (2013) Rebiopsy of Non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790 M mutation-positive and mutation-negative populations. Cancer 119:4325–4332
17. Hata A, Katakami N, Yoshioka H, Kaji R, Masago K, Fujita S et al (2015) Spatiotemporal T790 M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI. J Thorac Oncol 10(11):1553–1559
18. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM et al (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517–4520
19. Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S et al (2009) Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4:1415–1419
20. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R et al (2011) Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 3:90ra59